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Background: Several randomized trials and meta-analyses confirmed a wide benefit of radiotherapy (RT), both after
breast conserving surgery (BCS) and mastectomy. However, many elderly women don't receive RT. Hypofractionated
(HF) RT allows « simplified » and more accessible treatments with equivalent results to classic RT in three large
randomized trials. However, there are few available data on HF-RT for nodal irradiation, as well as for the boost.
Methods: We evaluated patients treated for IBC by HF-RT between 2004 and 2012 in two regional cancer centres. We
used an original scheme delivering 45 Gy in 15 fractions three times a week, both after BCS or mastectomy, with or
without nodal irradiation. After BCS, a 9 Gy boost in 3 fractions was delivered. Local, regional and distant recurrences
were assessed, as well as acute and late cutaneous, cardiac or pulmonary toxicities.
Results: 205 patients were analysed, 116 after BCS (57 %) and 89 after mastectomy (43 %). Median age was 81 years
(range: 52-91); 44 % had axillary nodal involvement (pN+). The Nottingham Prognostic Index (NPI) scored 0, 1, 2 and 3
in 10 %, 27 %, 44 % and 19 % of the cases. A nodal HF-RT was delivered in 65 patients (32 %) and boost in 98 patients
(84 % of BCS) by 9 Gy/3 fr scheme. Fifty (24 %) patients underwent chemotherapy and 156 (75 %) hormonal treatment.
With a 49-month median follow-up, 3/116 (2.6 %) patients and 4/89 (4.5 %) had local recurrence (LR) after BCS and
mastectomy, respectively. The overall 5-year LR rate was 4.4 %. In univariate and multivariate analysis, LR risk factors
were: high NPI (HR 5.46; p = 0.028), and triple negative tumour (HR 9.78; p = 0.006). Only 8 (4.5 %) patients had grade III
skin toxicity; 29 (14 %) late fibrosis and 16 (8 %) telangiectasia. No pulmonary or cardiac toxicity was observed.
Conclusion: Our HF-RT scheme (with or without nodal irradiation) confirms in elderly patients the data from randomized
trials, both after BCS or mastectomy. Toxicity seems very acceptable but requires a longer follow-up. A larger
evaluation is still ongoing in several other centres in France.
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In Western countries, breast cancer (BC) is the most
common female cancer, and occurs frequently in women
older than 70 [1]. In two large national surveys performed
in France (1155 patients) and Italy (3532 patients) in
2001–2002, BC rates in women older than 70 were 20.4
and 18.5 %, respectively [2, 3]. This rate reached almost
30 % in another Swiss study including 4820 patients
treated from 2003 to 2005 [4].
The benefit of post-operative irradiation was widely
confirmed by several studies, randomized trials [5, 6]
and meta-analyses (EBCTCG) [7], both after breast con-
serving surgery and mastectomy, but many studies
showed a clear undertreatment in older patients for vari-
ous reasons (e.g. difficult access to radiotherapy centres,
comorbidities). This fact induces higher local recurrence
(LR) rates and increases long-term mortality [8, 9]. Thus,
the International Society of Geriatric Oncology’s recent
guidelines strongly recommend the use of post-operative
RT in the same conditions as in a younger population,
whenever possible [1]. In order to facilitate the access to
radiotherapy centres and to simplify treatment modal-
ities, several schemes of «hypofractionated» RT (HFRT)
have been developed for 15–20 years, especially in UK and
Canada [10–12]. Other French centres have been using
«empirically» shortened schemes for many years [13–15].
However, due to a lack of data of the randomized trials on
HFRT and mastectomy, HFRT and lymph node irradiation
(LNI), and HFRT and chemotherapy, the use of a short-
ened scheme is not recommended yet in those situations.Methods
Data collection
We assessed 205 postmenopausal patients treated by
HFRT for a non-metastatic BC in two regional cancer
centres (Nantes and Angers) between June 2004 and
June 2012 both after breast conserving surgery (BCS)
or mastectomy.
For each patient, a file detailed the following items: BC
family history, age at menopause, hormone replacement
therapy (HRT), comorbidities, type of surgery (lumpec-
tomy/mastectomy), RT modalities (volumes/dose), chemo-
therapy and/or hormonal therapy.
The following histopathological features were also
assessed: tumour size, axillary nodal involvement (ANI),
histological subtype (ductal, lobular, mixed), SBR (Scarff,
Bloom and Richardson) grading, excision quality, pres-
ence of vascular or lymphatic emboli, Her-2 oncopro-
tein over-expression and hormone receptor status (HR).
The «Nottingham Prognostic Index» (NPI) score was
calculated taking into account tumour size, ANI and
SBR grading. The study was in accordance to the declar-
ation of Helsinki in its latest version.Radiotherapy techniques and dose equivalence
HFRT was delivered 4–8 weeks after surgery or 4–6
weeks after chemotherapy. A 45 Gy total dose in 15 frac-
tions (3 per week) was delivered to the whole breast
(with or without a 9 Gy boost in 3 fractions) or chest
wall, by two opposed tangential fields (4–10 MV pho-
tons). The boost was delivered by an anterior field (9–12
Mev electrons) or by two reduced tangential fields. In
case of nodal irradiation (supraclavicular fossa (SCF),
axilla or internal mammary chain (IMC)), the same
dose was delivered (45 Gy/15 fr, 3 fr/week). SCF and
axilla were treated by a 10 MV photon direct field (with
or without a complementary posterior field for axilla
according to dosimetry), and IMC by a direct field
using a combination of photons and electrons. Assum-
ing that α/δ = 3,5, the Biological Equivalent Dose (BED)
of 45 Gy/15 fr scheme was 52 Gy using the iLQ version
1.0 Calculator (by SFjRO, French Society of Young
Radiation Oncologist).
Toxicity assessment and follow-up
During the treatment, a weekly consultation was per-
formed by a radiation oncologist. The acute skin toxicity
was assessed by the CTCAE scale (Common Terminology
Criteria for Adverse Events). After treatment, the patients
were assessed twice a year in order to evaluate the onco-
logical outcome and possible toxicities (fibrosis, telangiec-
tasias, rib fractures, heart or lung sequelea). An annual
mammogram was performed as well as other exams in
case of clinical symptoms.
Statistics
The continuous variables were described by the median
[extreme values] and/or the mean ± standard deviation.
The qualitative variables were described by the distribu-
tion of their modalities. The evolutive variable (local
recurrence-free survival) was defined as the period
between the date of initial surgery and the date of local
recurrence of the date of last news without local recur-
rence. It was calculated using the Kaplan-Meier method.
The groups in question were compared using Student’s
test (or the Mann-Whitney non-parametric test if neces-
sary) for continuous variables and by Pearson’s Chi2 test
(or Fisher’s exact test if necessary) for qualitative vari-
ables. The local recurrence-free survival curves were
compared using the logrank test for the variables in clas-
ses and using the univariate Cox model for continuous
variables. The prognostic variables at the univariate stage
in addition to those with p < 0.15 were entered in the
multivariate Cox’s semi-parametric regression model.
The analyses were performed in bilateral formulation
and the p-value of significance was set at 5 %. The soft-
ware used was Stata 13.1 (StataCorp, College Station,
Texas 77845 USA).
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Patients characteristics
Median age was 81 years (range: 52–91) with 94 % over
70 years; 45 patients (22 %) had BC family history; among
all patients, only 18 (9 %) received HRT (median duration:
8 years). Among comorbidities, we observed heart failure,
severe respiratory disease or severe neurologic or osteoar-
ticular disease in 12, 5 and 32 % of the cases, respectively.
BC was discovered clinically in 61 % of the cases; 56 % of
BC were in the left side.
Histopathological characteristics of the entire popula-
tion are described in Table 1. Histological median tumour
size was 20 mm (3–70); 177 (86 %) were infiltrating ductal
carcinomas (IDC), 14 (7 %) infiltrating lobular carcinomas
(ILC), 4 mixed types and 10 other types; 90 patients
(44 %) had ANI. Among 144 evaluated cases, 32 (22 %)
had vascular emboli. Finally, 24 (12 %) tumours were
triple-negative (ER-, PgR-, Her-2-) and 18 had Her2 over-
expression (9 %).Table 1 Histopathological features of the population
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SBR Scarff Bloom et Richardson grading, NPI Nottingham prognostic indexTreatment modalities
Eighty-nine patients (43 %) underwent mastectomy and
116 (57 %) breast conserving surgery. For both groups,
the median follow-ups were 53 and 47 months (p = 0,37),
respectively. Table 2 summarizes radiotherapy modalities
for both groups. Globally, 65 patients (32 %) underwent
lymph node irradiation and 98 out of 116 (84 %) received
boost after whole breast irradiation. Among 50 (24 %)
patients undergoing chemotherapy (CT), 18 received a
TC (Taxotere-Cyclophosphamide) protocol, 11 FEC 50
(5FU, Epirubicin, Cyclophosphamide) protocol, 9 EC
100-Taxotere and 12 others. Among 156 (75 %) patients
undergoing hormonal treatment (HT), 150 received aro-
matase inhibitors and 6 Tamoxifen.Local recurrences
After a 49-month median follow-up, seven local recur-
rences (LR) occurred: 3 out of 116 (2,6 %) patients
treated by BCS and 4 out of 89 (4,5 %) treated by mast-
ectomy. The overall 5-year LR rate was 4.4 %. One pa-
tient with LR after BCS had synchronous metastases and
three patients with LR after mastectomy developed me-
tastases in the subsequent 4 months. All the patients re-
ceived chemotherapy (CT).
Table 3 details LR risk factors both in univariate and
multivariate analysis. In univariate analysis, significant
LR risk factors were high NPI (HR 5.46, p = 0.028), triple-
negative tumour (HR 9.78, p = 0.006), with a trend for ANI
(HR 6.97, p = 0.073). In multivariate analysis, only triple-
negative tumours remained significant (p = 0.021) and high
NPI was borderline (p = 0.058).Regional and distant failures
Five nodal recurrences (NR) occurred : four in axilla and
one in supraclavicular fossa. Two of these NR occurred
after nodal irradiation. The overall 5-year NR rate was
3,6 %. Twenty-five patients developed metastasis with a
28-month median delay: 10 bone, 4 lung and 1 liver; 10
patients had multiple sites involved.Table 2 Radiotherapy modalities among patients treated by
mastectomy and breast conserving surgery (BCS)
Mastectomy BCS
n (%) 89 (43 %) 116 (57 %)
LNRT n = 65 (32 %)a
Supraclavicular fossa (SCF) 40 24
Internal mammary chain (IMC) 16 6
axilla 5 3
Boost irradiation 4 (4.5 %) 98 (84 %)
LNRT lymphnodal irradiation with multiple fields possible
amultiple fields possible
Table 3 Local reccurence risk factors
Univariate analysis Multivariate analysis
Variable HR p HR p
(95 % CI) (95 % CI)
Mastectomy 1.61 (0.36–7.19) 0.534 - -
RT duration >42d. 0.50 (0.06–4.15) 0.521 - -
ANI (pN+) 6.97 (0.83–58.2) 0.073 - -
Delay between surgery and RT >42 d. - 0.371 - -
SBR III 2.95 (0.65–13.40) 0.161 - -
Triple negative 9.78 (1.90–50.29) 0.006 7.19 (1.35–38.17) 0.021
Chemotherapy 6.81 (1.30–35.76) 0.023 - -
Age 1.03 (0.90–1.19) 0.638 - -
NPI (overall) 1.98 (1.08–3.65) 0.028 1.94 (0.98–3.86) 0.058
NPI 3 (vs 0-1-2) 5.46 (1.21–24.64) 0.027 - -
RT radiotherapy, ANI axillary nodal involvement (pN+), SBR Scarff, Bloom and Richardson grading, NPI: Nottingham prognostic index, d days
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The 3- and 5-year specific survival rates were 94 and
91.3 % respectively. Forty-two (20,5 %) patients died, in-
cluding 15 by metastases, 24 by intercurrent disease and
3 of second cancer.
Toxicities
Table 4 shows the early and late skin toxicity rates ac-
cording to treatments.
Twenty-nine (14 %) patients had no acute skin tox-
icity; 133 (65 %), 35 (17 %) and 8 (4 %) had respectively
grade I, II and III cutaneous toxicity (radio-epithelitis).
Among 8 patients with grade III toxicity, only one under-
went chemotherapy. Four patients with grade III toxicity
required a 7–10 days stop during the treatment.
Thirty (14.6 %) patients had late fibrosis and 17 (8 %)
telangiectasia. Telangiectasia was correlated to occurrence
of grade II-III radio-epithelitis during the treatment (grade
I: 5.6 % versus grade II-III: 19 %, Fisher’s test, p = 0.011).
No cardiac or pulmonary toxicities were observed, neither
were plexopathy or rib fractures.Table 4 Skin toxicity
Toxicity Breast
Boost / No boo
n = 98
Acute Skin Grade 1 54 (55 %)
Grade 2 25 (26 %)
Grade 3 6 (6 %)
Late Skin Fibrosis 24 (24 %)
Telangiectasias 13 (13 %)
hyperpigmentation 7 (7 %)
aSupraclavicular fossa
binternal mammary chainDiscussion
BC in elderly women is an increasingly important issue,
representing about 25 % of all BC [1–4]. Unfortunately,
there are relatively few data on this population, because
most of the trials exclude women over 70. However, sev-
eral studies reported a clear “undertreatment”, both for
locoregional and systemic treatment in elderly women,
increasing the LR and death risks [9, 16–18]. Moreover,
many physicians believe that BC in elderly is a “less ag-
gressive” disease than in young women. This is true when
compared to women under 40, but not with 40–69-year-
old patients [19, 20]. Finally, distance from and/or rarity
of radiotherapy centres and comorbidities are additional
difficulties to optimize RT use in the elderly.
This is one of the main reasons of the development of
“alternative/concentrated” RT schemes also called hypo-
fractionated (HF) [21]. After many radiobiological ana-
lyses [22], several schemes were proposed, especially in
UK and Canada. Three randomized trials confirmed
equivalent results on local control and specific mortality
between classical and HF-RT [10–12, 21] (Table 5).Chest wall SCFa IMCb
st wall
n = 18 n = 89 n = 64 n = 22
9 (50 %) 70 (79 %) 29 (45 %) 14 (64 %)
5 (28 %) 5 (6 %) - 1 (5 %)
2 (11 %) - 1 (2 %) -
3 (17 %) 3 (3 %) - -
1 (6 %) 3 (3 %) - -
- 1 (1 %) - -
Table 5 Description of the trials assessing hypofractionation (HF)
Reference Type Cohort (HF) HF Mastectomy Boost Lymph node RT 5-year LR
Whelan [12] P. 622 42.5 Gy/16 fr 0 % 0 % 0 % PFS 97.2 %
Owen [35] P. 940 42.9 Gy/13 fr 0 % 75 % 21 % 7 %
39 Gy/13 fr 9 %
Start A [11] P. 1487 41.6 Gy/13 fr 15 % 61 % 13.2 % 3.2 %
39 Gy/13 fr 4.6 %
Start B [10] P. 1110 40 Gy/15 fr 8 % 43.8 % 7.4 % 2 %
Cutuli [2] R. +CA 133 32.5 Gy/5 fr 0 % 55 % 48 % 3.7 %
Ortholan [14] R. 150 32.5 Gy/5 fr 28.5 % 33,00 % 32 % -
Kirova [15] R. +CA 50 32.5 Gy/5 fr 0 % 0 % - -
P prospective randomized, R retrospective, + CA with control arm, Gr gray, fr fractions, PFS progression-free survival, LR local recurrence
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fractions over 22 days [12], and included only women
treated by BCS. The English START A Trial HF-RT arm
delivered 41,6 Gy or 39 Gy in 13 fractions and 35 days,
and included 85 % of BCS and 15 % of mastectomy [11].
In the subsequent START B Trial experimental arm,
40 Gy in 15 fractions and 21 days were delivered, 92 %
after BCS [10]. These schemes are now validated by the
French guidelines on infiltrating BC [23] for postmeno-
pausal women with pT1T2N0 lesions and positive hor-
mone receptors.
However, other schemes were used almost exclusively
in elderly patients, often with many comorbidities. A sin-
gle dose of 6,5 Gy per fraction each week (total: 5 or 6
fractions) was used at least in three reports [13–15, 24].
In France, another “empirical” approach was used in
order to simplify treatment for elderly, with 42 or 45 Gy
in 14 or 15 fractions over 4–5 weeks both after BCS or
mastectomy. From a radiobiological point of view, as-
suming a 3.5 α/δ ratio for breast cancer, the biological
equivalent dose (BED) of our scheme is approximately
52 Gy (classical fractionation) and 64 Gy if boost was
applied. To our knowledge, our study is the first one
evaluating this 45 Gy/15 fr/35 days scheme (+/− 9 Gy/3
fr. Boost), especially after mastectomy. It should be noted
that in the START A and B trials 336 (15 %) and 177 pa-
tients (8 %) underwent mastectomy, but the data on nodal
RT (supraclavicular fossa ± axilla, but never IMC) in these
patients remain unclear, without technical details and no
specific choice criteria. In a series from Thailand, 148
patients treated by mastectomy received HFRT, using an
almost identical scheme to the Canadian Trial. With a 39-
month follow-up, the local control rate was 86 %, without
toxicity differences in comparison with 77 patients treated
by a conventional scheme [25].
Despite a relatively short follow-up, our results seem
to be consistent with the literature data, leading to an
approximately 0,8 % LR rate a year [26, 27]. Acute cuta-
neous toxicity was acceptable with less than 5 % of grade3 reaction. No long-term toxicity, particularly cardiac
toxicity, was detected, whereas 56 % of the irradiations
involved the left-hand side. Our results may be partly
explained by a short hindsight, since cardiac toxicity is
known to appear at a late stage. In the START trials,
0.8–1.4 % symptomatic pulmonary fibrosis, 1.3–1.5 %
rib fractures and 2 % ischemic heart diseases were ob-
served [10, 11]. In a study from Pakistan comparing
three HFRT schemes, the cardiac toxicity was approxi-
mately 5 %, but the treatments were delivered only by
Cobalt photons [28].
To date, there have been no recommendations relating
to lymph node area irradiation in a hypofractionated
schedule. Indeed, this was not performed in the Canad-
ian trial or in the retrospective trial of Dragun [24],
whereas lymph node irradiation was performed in 13.2
and 7.4 % of the patients in the START A and B trials
respectively according to each centre’s policy. In our
study, HFRT of the axilla, internal mammary chain and
supraclavicular area were performed in 4, 11 and 31 %
of the cases respectively. Nodal irradiation slightly in-
creased the long-term cardiac death in several older
studies, but the rates decreased widely with the use of
modern RT techniques, such as clearly shown in the
Danish trials widely using electrons to treat chest wall
and more particularly IMC [29]. There was no signifi-
cant influence of fraction dose [30]. In our series, no
cardiac or pulmonary toxicities were observed, whereas
66 patients (32 %) underwent nodal irradiation. Unfortu-
nately, we have no precise data on lymphoedema occur-
rence, but the few available literature data do not report
any increased lymphoedema incidence among the pa-
tients treated by HFRT [31].
In our study, 84 % of the patients treated by BCS
underwent a 9 Gy/3 fr boost, whereas there are no data
on this modality in the literature, especially in women
over 70. Due to the very low rate of LR, the impact of
boost is not evaluable; as to skin toxicity, the rate is
similar to those patients without boost, as well as for
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sis (24 vs 17 %). This rate is quite similar to those ob-
served (26 %) in boost arm in the EORTC Trial [32].
On the other hand, we found in this very old popula-
tion only 37 % of deaths by breast cancer versus 63 % of
deaths due to intercurrent disease, including second
cancers.
This point is extremely important and has been con-
firmed by several other reports. In a Franco-Italian study
including 927 patients over 70 treated by BCS + RT, the
overall breast cancer death rate was 33 %, and such rate
decreased according to age (36, 28 and 24 % in 70–75,
76–80 and >80 year groups), due to the influence of
intercurrent diseases [13].
Conclusions
Finally, our study confirms a good local control rate by
HFRT in elderly women without severe toxicities similar
to those observed in classical RT, even in case of nodal
irradiation. These results confirm the results reported by
others, including long-term data from meta-analysis
[2, 10, 11, 14, 15, 33–35]. The impact of locoregional re-
currence is clinically and psychologically important, even
in elderly people [1], and except in case of very heavy
comorbidities, an optimal treatment should be proposed
in these women, including in case of LR risk factors
boost after WBI. Our scheme is quite simple, similar to
others used in randomized trials and seems very feasible
and adaptable for many elderly patients.
A prospective survey on this RT modality is currently
under evaluation in several other centres in France.
However, HFRT must strictly comply with the optimal
radiotherapy guidelines, both for breast and node irradi-
ation, in order to avoid “hot spots” with a possible risk
of long-term side effects, especially when associated to
chemotherapy [36, 37].
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